Zurich, 20 May 2026
Important information
The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements.
Making selfcare simpler and easier
We benefit from multiple structural growth drivers
Selfcare
Move from IV to subcutaneous delivery to enhance quality of life, encouraging therapy adherence and lower healthcare cost
Biologics
Next generation drugs are mostly large molecules that must be
injected
Biosimilars
Expanding access to affordable medical care worldwide
Incretins
Transforming healthcare and society, improving public health, productivity, and quality of life for millions
Ypsomed has completed its transformational journey to become a pure-play self-injection specialist
Ypsomed is now a pure-play self-injection specialist
2026
2025
2025
2024
2023
2022
Phase-out of contract manufacturing delivery systems
Completion of the sale of Ypsotec
Completion of the sale of the diabetes care business
Completion of the sale of the pen needle and blood glucose monitoring business
Completion of the sale of the DiaExpert retail business in Germany
Transformation from matrix structure to an organization with product areas
Thanks to its clear strategic focus, Ypsomed is uniquely positioned to continue to benefit from significant growth
Platforms
Innovation
Operational
Excellence
Strong Financials
Ypsomed offers the broadest range of self-injection solutions on the market
Platforms
Innovation
Operational
Excellence
Strong Financials
Ypsomed offers the broadest range of self-injection solutions on the market
Ypsomed won a record number of 44 new projects in FY 2025/26, thereof 12 with new customers
New project wins FY 2025/26
Illustrative
44 new project wins
Ypsomed wins across the board
Various therapeutic areas
Originators and biosimilars
Developed and emerging markets
New and existing pharma customers
Sustained growth momentum ahead
Incretin Originator
Non-incretin Originator
Incretin Biosimilar
Non-incretin Biosimilar
Ypsomed has a diversified customer portfolio with no customer exceeding 15 % of revenue in the foreseeable futureCommercial sales by customer FY 2025/26
Illustrative
over 130
customers
Increasingly diversified portfolio
>130 customers
No single customer accounts for more than 15 % of commercial revenue
Even less concentration at the EBIT level, today and in the foreseeable future
Ypsomed supports patients with over 80 approved products in 25 indications 80+ Products approved
Pens
Diabetes
Fertility
Growth Disorders
Obesity
Osteoporosis
Parkinson
Polycythaemia Vera
Hypoparathyroidism
Autoinjectors
Asthma
Alzheimer
Atopic Dermatitis
ATTR Amyloidosis
Hypercholesterolemia
Crohn's Disease
Migraine
Multiple Sclerosis
Obesity
Oncology
Osteoporosis
Psoriasis
Rheumatoid Arthritis
Sexual dysfunction
Hereditary Angioedema
Fam. Chylomicronemia Syndrome
Acromegaly
Lupus
Neuromyelitis optica spectrum disorder
Platforms
Innovation
Operational
Excellence
Strong Financials
We announced three new devices platforms in FY 2025/26, all based on
Ypsomed's eco-design guidelines
YpsoLoop won several awards
CPHI
innovation
award
Pharmapack patient-centric design award
Red Dot product design award
Sustainability is embedded in Ypsomed's products, supply chain, and operations and cements our innovation leadership
Eco-designed products Reduce dependencies
Carbon-reduced supply chain
Meet customer scope 3
requirements
Energy-efficient sites
Less cost volatility and
improved bottom line
Clear-to-Clinic accelerates time to market thanks to pre-validated platforms
Clinic-ready devices
available in <6 months
Documentation Verification Parallelization Early readiness
Ypsomed expands globally
Platforms
Innovation
Operational
Excellence
Strong Financials
Ypsomed builds a global manufacturing footprint, producing local for local
Holly Springs (USA)
opening 2027
Schwerin (DE) Schwerin II (DE)
opening 2026
Burgdorf HQ (CH)
Solothurn (CH)
Burgdorf (CH) Burgdorf (CH)
Suzhou (CN) (Contract Manuf.)
Changzhou (CN)
In Solothurn we opened our new tool manufacturing facility in April 2026
And we are phasing out Contract Manufacturing to focus on proprietary autoinjectors until end of 2026
In our Changzhou site commercial production has started end of 2025